CLOs on the Move

Allarity Therapeutics

www.allarity.com

 
Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Cambridge, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.allarity.com
  • 210 Broadway # 201
    Cambridge, MA USA 02139
  • Phone: 401.426.4664

Executives

Name Title Contact Details

Similar Companies

Gastro Care Partners

Gastro Care Partners is the national partner for successful regional gastroenterology practices. We equip practices with the resources necessary to thrive.

Capsugel

Capsugel is a Peapack, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

NovaBioMed Inc

NovaBioMed Inc is a Kentville, NS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Nanōmix

Nanōmix is the leader in mobile point-of-care diagnostics for use where time and accuracy is critical.

Radius Health

Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius` RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.